APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Influenza A Virus, H3N2 Subtype Infections Drug

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Influenza A Virus, H3N2 Subtype Infections Drug Industry Growth and Trends Forecast to 2032

Report ID 174002650119 December 2025113 pages

Choose your research edition.

Industry ResearchInfluenza A Virus, H3N2 Subtype Infections Drug Industry Research Report 2026135 pages · $2,950 USDIndustry Growth & TrendsGlobal Influenza A Virus, H3N2 Subtype Infections Drug Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Influenza A Virus, H3N2 Subtype Infections Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Influenza A Virus, H3N2 Subtype Infections Drug Market Outlook and Growth Opportunities 2026203 pages · $4,250 USDMarket Analysis & ForecastGlobal Influenza A Virus, H3N2 Subtype Infections Drug Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

The global Influenza A Virus, H3N2 Subtype Infections Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Influenza A Virus, H3N2 Subtype Infections Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Influenza A Virus, H3N2 Subtype Infections Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Influenza A Virus, H3N2 Subtype Infections Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Influenza A Virus, H3N2 Subtype Infections Drug include Johnson & Johnson, AbbVie Inc, Zydus Cadila Healthcare Limited, Visterra, Inc., VBI Vaccines Inc., Sarepta Therapeutics, Inc., OPKO Health, Inc., NanoViricides, Inc. and Mucosis B.V., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Influenza A Virus, H3N2 Subtype Infections Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Influenza A Virus, H3N2 Subtype Infections Drug market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Influenza A Virus, H3N2 Subtype Infections Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Influenza A Virus, H3N2 Subtype Infections Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Influenza A Virus, H3N2 Subtype Infections Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Influenza A Virus, H3N2 Subtype Infections Drug Market by Company

Johnson & Johnson

AbbVie Inc

Zydus Cadila Healthcare Limited

Visterra, Inc.

VBI Vaccines Inc.

Sarepta Therapeutics, Inc.

OPKO Health, Inc.

NanoViricides, Inc.

Mucosis B.V.

MedImmune, LLC

Medicago Inc.

Inovio Pharmaceuticals, Inc.

ILiAD Biotechnologies, LLC

Glide Pharmaceutical Technologies Limited

FluGen, Inc.

Celltrion, Inc.

Aphios Corporation

AIMM Therapeutics B.V.

Influenza A Virus, H3N2 Subtype Infections Drug Segment by Type

NVINF-1

NSC-61610

NP-025

NEO-8877

Others

Influenza A Virus, H3N2 Subtype Infections Drug Segment by Application

Clinic

Hospital

Others

Influenza A Virus, H3N2 Subtype Infections Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Influenza A Virus, H3N2 Subtype Infections Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Influenza A Virus, H3N2 Subtype Infections Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Influenza A Virus, H3N2 Subtype Infections Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Influenza A Virus, H3N2 Subtype Infections Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Influenza A Virus, H3N2 Subtype Infections Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of NVINF-1 Table 2. Major Company of NSC-61610 Table 3. Major Company of NP-025 Table 4. Major Company of NEO-8877 Table 5. Major Company of Others Table 6. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Type (2021-2026) & (K Units) Table 8. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share in Volume by Type (2021-2026) Table 9. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Type (2021-2026) & (US$ Million) Table 10. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share in Value by Type (2021-2026) Table 11. Global Influenza A Virus, H3N2 Subtype Infections Drug Price by Type (2021-2026) & (US$/Unit) Table 12. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Type (2027-2032) & (K Units) Table 13. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share in Volume by Type (2027-2032) Table 14. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Type (2027-2032) & (US$ Million) Table 15. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share in Value by Type (2027-2032) Table 16. Global Influenza A Virus, H3N2 Subtype Infections Drug Price by Type (2027-2032) & (US$/Unit) Table 17. North America Influenza A Virus, H3N2 Subtype Infections Drug Sales by Type (2021-2026) & (K Units) Table 18. North America Influenza A Virus, H3N2 Subtype Infections Drug Sales by Type (2021-2026) & (US$ Million) Table 19. Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales by Type (2021-2026) & (K Units) Table 20. Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales by Type (2021-2026) & (US$ Million) Table 21. Asia-Pacific Influenza A Virus, H3N2 Subtype Infections Drug Sales by Type (2021-2026) & (K Units) Table 22. Asia-Pacific Influenza A Virus, H3N2 Subtype Infections Drug Sales by Type (2021-2026) & (US$ Million) Table 23. Latin America Influenza A Virus, H3N2 Subtype Infections Drug Sales by Type (2021-2026) & (K Units) Table 24. Latin America Influenza A Virus, H3N2 Subtype Infections Drug Sales by Type (2021-2026) & (US$ Million) Table 25. Middle East and Africa Influenza A Virus, H3N2 Subtype Infections Drug Sales by Type (2021-2026) & (K Units) Table 26. Middle East and Africa Influenza A Virus, H3N2 Subtype Infections Drug Sales by Type (2021-2026) & (US$ Million) Table 27. Influenza A Virus, H3N2 Subtype Infections Drug Industry Trends Table 28. Influenza A Virus, H3N2 Subtype Infections Drug Industry Drivers Table 29. Influenza A Virus, H3N2 Subtype Infections Drug Industry Opportunities and Challenges Table 30. Influenza A Virus, H3N2 Subtype Infections Drug Industry Restraints Table 31. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Revenue by Company (US$ Million) & (2021-2026) Table 32. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue Market Share by Company (2021-2026) Table 33. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Company (2021-2026) & (K Units) Table 34. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Share by Company (2021-2026) Table 35. Global Influenza A Virus, H3N2 Subtype Infections Drug Market Price by Company (2021-2026) & (US$/Unit) Table 36. Global Influenza A Virus, H3N2 Subtype Infections Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 37. Global Influenza A Virus, H3N2 Subtype Infections Drug Major Company Production Sites and Headquarters Table 38. Global Influenza A Virus, H3N2 Subtype Infections Drug Company, Product Type & Application Table 39. Global Influenza A Virus, H3N2 Subtype Infections Drug Company Establishment Date Table 40. Global Company Market Concentration Ratio (CR5 and HHI) Table 41. Global Influenza A Virus, H3N2 Subtype Infections Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 42. Global Influenza A Virus, H3N2 Subtype Infections Drug Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 43. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Region (2021-2026) & (K Units) Table 44. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share in Volume by Region (2021-2026) Table 45. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Region (2021-2026) & (US$ Million) Table 46. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share in Value by Region (2021-2026) Table 47. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 48. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Region (2027-2032) & (K Units) Table 49. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share in Volume by Region (2027-2032) Table 50. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Region (2027-2032) & (US$ Million) Table 51. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share in Value by Region (2027-2032) Table 52. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 53. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 54. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Application (2021-2026) & (K Units) Table 55. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share in Volume by Application (2021-2026) Table 56. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Application (2021-2026) & (US$ Million) Table 57. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share in Value by Application (2021-2026) Table 58. Global Influenza A Virus, H3N2 Subtype Infections Drug Price by Application (2021-2026) & (US$/Unit) Table 59. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Application (2027-2032) & (K Units) Table 60. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share in Volume by Application (2027-2032) Table 61. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Application (2027-2032) & (US$ Million) Table 62. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share in Value by Application (2027-2032) Table 63. Global Influenza A Virus, H3N2 Subtype Infections Drug Price by Application (2027-2032) & (US$/Unit) Table 64. North America Influenza A Virus, H3N2 Subtype Infections Drug Sales by Application (2021-2026) & (K Units) Table 65. North America Influenza A Virus, H3N2 Subtype Infections Drug Sales by Application (2021-2026) & (US$ Million) Table 66. Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales by Application (2021-2026) & (K Units) Table 67. Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales by Application (2021-2026) & (US$ Million) Table 68. Asia-Pacific Influenza A Virus, H3N2 Subtype Infections Drug Sales by Application (2021-2026) & (K Units) Table 69. Asia-Pacific Influenza A Virus, H3N2 Subtype Infections Drug Sales by Application (2021-2026) & (US$ Million) Table 70. Latin America Influenza A Virus, H3N2 Subtype Infections Drug Sales by Application (2021-2026) & (K Units) Table 71. Latin America Influenza A Virus, H3N2 Subtype Infections Drug Sales by Application (2021-2026) & (US$ Million) Table 72. Middle East and Africa Influenza A Virus, H3N2 Subtype Infections Drug Sales by Application (2021-2026) & (K Units) Table 73. Middle East and Africa Influenza A Virus, H3N2 Subtype Infections Drug Sales by Application (2021-2026) & (US$ Million) Table 74. Johnson & Johnson Company Information Table 75. Johnson & Johnson Business Overview Table 76. Johnson & Johnson Influenza A Virus, H3N2 Subtype Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Johnson & Johnson Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio Table 78. Johnson & Johnson Recent Development Table 79. AbbVie Inc Company Information Table 80. AbbVie Inc Business Overview Table 81. AbbVie Inc Influenza A Virus, H3N2 Subtype Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. AbbVie Inc Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio Table 83. AbbVie Inc Recent Development Table 84. Zydus Cadila Healthcare Limited Company Information Table 85. Zydus Cadila Healthcare Limited Business Overview Table 86. Zydus Cadila Healthcare Limited Influenza A Virus, H3N2 Subtype Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Zydus Cadila Healthcare Limited Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio Table 88. Zydus Cadila Healthcare Limited Recent Development Table 89. Visterra, Inc. Company Information Table 90. Visterra, Inc. Business Overview Table 91. Visterra, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Visterra, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio Table 93. Visterra, Inc. Recent Development Table 94. VBI Vaccines Inc. Company Information Table 95. VBI Vaccines Inc. Business Overview Table 96. VBI Vaccines Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. VBI Vaccines Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio Table 98. VBI Vaccines Inc. Recent Development Table 99. Sarepta Therapeutics, Inc. Company Information Table 100. Sarepta Therapeutics, Inc. Business Overview Table 101. Sarepta Therapeutics, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Sarepta Therapeutics, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio Table 103. Sarepta Therapeutics, Inc. Recent Development Table 104. OPKO Health, Inc. Company Information Table 105. OPKO Health, Inc. Business Overview Table 106. OPKO Health, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. OPKO Health, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio Table 108. OPKO Health, Inc. Recent Development Table 109. NanoViricides, Inc. Company Information Table 110. NanoViricides, Inc. Business Overview Table 111. NanoViricides, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. NanoViricides, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio Table 113. NanoViricides, Inc. Recent Development Table 114. Mucosis B.V. Company Information Table 115. Mucosis B.V. Business Overview Table 116. Mucosis B.V. Influenza A Virus, H3N2 Subtype Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Mucosis B.V. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio Table 118. Mucosis B.V. Recent Development Table 119. MedImmune, LLC Company Information Table 120. MedImmune, LLC Business Overview Table 121. MedImmune, LLC Influenza A Virus, H3N2 Subtype Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. MedImmune, LLC Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio Table 123. MedImmune, LLC Recent Development Table 124. Medicago Inc. Company Information Table 125. Medicago Inc. Business Overview Table 126. Medicago Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Medicago Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio Table 128. Medicago Inc. Recent Development Table 129. Inovio Pharmaceuticals, Inc. Company Information Table 130. Inovio Pharmaceuticals, Inc. Business Overview Table 131. Inovio Pharmaceuticals, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. Inovio Pharmaceuticals, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio Table 133. Inovio Pharmaceuticals, Inc. Recent Development Table 134. ILiAD Biotechnologies, LLC Company Information Table 135. ILiAD Biotechnologies, LLC Business Overview Table 136. ILiAD Biotechnologies, LLC Influenza A Virus, H3N2 Subtype Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 137. ILiAD Biotechnologies, LLC Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio Table 138. ILiAD Biotechnologies, LLC Recent Development Table 139. Glide Pharmaceutical Technologies Limited Company Information Table 140. Glide Pharmaceutical Technologies Limited Business Overview Table 141. Glide Pharmaceutical Technologies Limited Influenza A Virus, H3N2 Subtype Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 142. Glide Pharmaceutical Technologies Limited Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio Table 143. Glide Pharmaceutical Technologies Limited Recent Development Table 144. FluGen, Inc. Company Information Table 145. FluGen, Inc. Business Overview Table 146. FluGen, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 147. FluGen, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio Table 148. FluGen, Inc. Recent Development Table 149. Celltrion, Inc. Company Information Table 150. Celltrion, Inc. Business Overview Table 151. Celltrion, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 152. Celltrion, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio Table 153. Celltrion, Inc. Recent Development Table 154. Aphios Corporation Company Information Table 155. Aphios Corporation Business Overview Table 156. Aphios Corporation Influenza A Virus, H3N2 Subtype Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 157. Aphios Corporation Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio Table 158. Aphios Corporation Recent Development Table 159. AIMM Therapeutics B.V. Company Information Table 160. AIMM Therapeutics B.V. Business Overview Table 161. AIMM Therapeutics B.V. Influenza A Virus, H3N2 Subtype Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 162. AIMM Therapeutics B.V. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio Table 163. AIMM Therapeutics B.V. Recent Development Table 164. North America Influenza A Virus, H3N2 Subtype Infections Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 165. North America Influenza A Virus, H3N2 Subtype Infections Drug Sales by Country (2021-2026) & (K Units) Table 166. North America Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share by Country (2021-2026) Table 167. North America Influenza A Virus, H3N2 Subtype Infections Drug Sales Forecast by Country (2027-2032) & (K Units) Table 168. North America Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share Forecast by Country (2027-2032) Table 169. North America Influenza A Virus, H3N2 Subtype Infections Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 170. North America Influenza A Virus, H3N2 Subtype Infections Drug Market Size by Country (2021-2026) & (US$ Million) Table 171. North America Influenza A Virus, H3N2 Subtype Infections Drug Market Share by Country (2021-2026) Table 172. North America Influenza A Virus, H3N2 Subtype Infections Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 173. North America Influenza A Virus, H3N2 Subtype Infections Drug Market Share Forecast by Country (2027-2032) Table 174. Europe Influenza A Virus, H3N2 Subtype Infections Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 175. Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales by Country (2021-2026) & (K Units) Table 176. Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share by Country (2021-2026) Table 177. Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales Forecast by Country (2027-2032) & (K Units) Table 178. Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share Forecast by Country (2027-2032) Table 179. Europe Influenza A Virus, H3N2 Subtype Infections Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 180. Europe Influenza A Virus, H3N2 Subtype Infections Drug Market Size by Country (2021-2026) & (US$ Million) Table 181. Europe Influenza A Virus, H3N2 Subtype Infections Drug Market Share by Country (2021-2026) Table 182. Europe Influenza A Virus, H3N2 Subtype Infections Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 183. Europe Influenza A Virus, H3N2 Subtype Infections Drug Market Share Forecast by Country (2027-2032) Table 184. Asia-Pacific Influenza A Virus, H3N2 Subtype Infections Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 185. Asia-Pacific Influenza A Virus, H3N2 Subtype Infections Drug Sales by Country (2021-2026) & (K Units) Table 186. Asia-Pacific Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share by Country (2021-2026) Table 187. Asia-Pacific Influenza A Virus, H3N2 Subtype Infections Drug Sales Forecast by Country (2027-2032) & (K Units) Table 188. Asia-Pacific Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share Forecast by Country (2027-2032) Table 189. Asia-Pacific Influenza A Virus, H3N2 Subtype Infections Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 190. Asia-Pacific Influenza A Virus, H3N2 Subtype Infections Drug Market Size by Country (2021-2026) & (US$ Million) Table 191. Asia-Pacific Influenza A Virus, H3N2 Subtype Infections Drug Market Share by Country (2021-2026) Table 192. Asia-Pacific Influenza A Virus, H3N2 Subtype Infections Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 193. Asia-Pacific Influenza A Virus, H3N2 Subtype Infections Drug Market Share Forecast by Country (2027-2032) Table 194. Latin America Influenza A Virus, H3N2 Subtype Infections Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 195. Latin America Influenza A Virus, H3N2 Subtype Infections Drug Sales by Country (2021-2026) & (K Units) Table 196. Latin America Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share by Country (2021-2026) Table 197. Latin America Influenza A Virus, H3N2 Subtype Infections Drug Sales Forecast by Country (2027-2032) & (K Units) Table 198. Latin America Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share Forecast by Country (2027-2032) Table 199. Latin America Influenza A Virus, H3N2 Subtype Infections Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 200. Latin America Influenza A Virus, H3N2 Subtype Infections Drug Market Size by Country (2021-2026) & (US$ Million) Table 201. Latin America Influenza A Virus, H3N2 Subtype Infections Drug Market Share by Country (2021-2026) Table 202. Latin America Influenza A Virus, H3N2 Subtype Infections Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 203. Latin America Influenza A Virus, H3N2 Subtype Infections Drug Market Share Forecast by Country (2027-2032) Table 204. Middle East and Africa Influenza A Virus, H3N2 Subtype Infections Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 205. Middle East and Africa Influenza A Virus, H3N2 Subtype Infections Drug Sales by Country (2021-2026) & (K Units) Table 206. Middle East and Africa Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share by Country (2021-2026) Table 207. Middle East and Africa Influenza A Virus, H3N2 Subtype Infections Drug Sales Forecast by Country (2027-2032) & (K Units) Table 208. Middle East and Africa Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share Forecast by Country (2027-2032) Table 209. Middle East and Africa Influenza A Virus, H3N2 Subtype Infections Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 210. Middle East and Africa Influenza A Virus, H3N2 Subtype Infections Drug Market Size by Country (2021-2026) & (US$ Million) Table 211. Middle East and Africa Influenza A Virus, H3N2 Subtype Infections Drug Market Share by Country (2021-2026) Table 212. Middle East and Africa Influenza A Virus, H3N2 Subtype Infections Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 213. Middle East and Africa Influenza A Virus, H3N2 Subtype Infections Drug Market Share Forecast by Country (2027-2032) Table 214. Key Raw Materials Table 215. Raw Materials Key Suppliers Table 216. Influenza A Virus, H3N2 Subtype Infections Drug Distributors List Table 217. Influenza A Virus, H3N2 Subtype Infections Drug Customers List Table 218. Research Programs/Design for This Report Table 219. Authors List of This Report Table 220. Secondary Sources Table 221. Primary Sources List of Figures Figure 1. Influenza A Virus, H3N2 Subtype Infections Drug Image Figure 2. Global Influenza A Virus, H3N2 Subtype Infections Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Influenza A Virus, H3N2 Subtype Infections Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales (2021-2032) & (K Units) Figure 5. NVINF-1 Image Figure 6. Global NVINF-1 Sales YoY Growth (2021-2032) & (K Units) Figure 7. NSC-61610 Image Figure 8. Global NSC-61610 Sales YoY Growth (2021-2032) & (K Units) Figure 9. NP-025 Image Figure 10. Global NP-025 Sales YoY Growth (2021-2032) & (K Units) Figure 11. NEO-8877 Image Figure 12. Global NEO-8877 Sales YoY Growth (2021-2032) & (K Units) Figure 13. Others Image Figure 14. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 15. Global Influenza A Virus, H3N2 Subtype Infections Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 16. Global Influenza A Virus, H3N2 Subtype Infections Drug Market Share by Type 2025 VS 2032 Figure 17. North America Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share in Volume by Type in 2025 Figure 18. North America Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share in Value by Type in 2025 Figure 19. Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share in Volume by Type in 2025 Figure 20. Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share in Value by Type in 2025 Figure 21. Asia-Pacific Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share in Volume by Type in 2025 Figure 22. Asia-Pacific Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share in Value by Type in 2025 Figure 23. Latin America Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share in Volume by Type in 2025 Figure 24. Latin America Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share in Value by Type in 2025 Figure 25. Middle East and Africa Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share in Volume by Type in 2025 Figure 26. Middle East and Africa Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share in Value by Type in 2025 Figure 27. Global Top 5 and 10 Influenza A Virus, H3N2 Subtype Infections Drug Players Market Share by Revenue in 2025 Figure 28. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Clinic Image Figure 30. Global Clinic Sales YoY Growth (2021-2032) & (K Units) Figure 31. Hospital Image Figure 32. Global Hospital Sales YoY Growth (2021-2032) & (K Units) Figure 33. Others Image Figure 34. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 35. Global Influenza A Virus, H3N2 Subtype Infections Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 36. Global Influenza A Virus, H3N2 Subtype Infections Drug Market Share by Application 2025 VS 2032 Figure 37. North America Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share in Volume by Application in 2025 Figure 38. North America Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share in Value by Application in 2025 Figure 39. Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share in Volume by Application in 2025 Figure 40. Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share in Value by Application in 2025 Figure 41. Asia-Pacific Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share in Volume by Application in 2025 Figure 42. Asia-Pacific Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share in Value by Application in 2025 Figure 43. Latin America Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share in Volume by Application in 2025 Figure 44. Latin America Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share in Value by Application in 2025 Figure 45. Middle East and Africa Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share in Volume by Application in 2025 Figure 46. Middle East and Africa Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share in Value by Application in 2025 Figure 47. North America Influenza A Virus, H3N2 Subtype Infections Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 48. North America Influenza A Virus, H3N2 Subtype Infections Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. North America Influenza A Virus, H3N2 Subtype Infections Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. North America Influenza A Virus, H3N2 Subtype Infections Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 52. Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe Influenza A Virus, H3N2 Subtype Infections Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Europe Influenza A Virus, H3N2 Subtype Infections Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Influenza A Virus, H3N2 Subtype Infections Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 56. Asia-Pacific Influenza A Virus, H3N2 Subtype Infections Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Asia-Pacific Influenza A Virus, H3N2 Subtype Infections Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Asia-Pacific Influenza A Virus, H3N2 Subtype Infections Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Influenza A Virus, H3N2 Subtype Infections Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 60. Latin America Influenza A Virus, H3N2 Subtype Infections Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America Influenza A Virus, H3N2 Subtype Infections Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Latin America Influenza A Virus, H3N2 Subtype Infections Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Influenza A Virus, H3N2 Subtype Infections Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 64. Middle East and Africa Influenza A Virus, H3N2 Subtype Infections Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 65. Middle East and Africa Influenza A Virus, H3N2 Subtype Infections Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 66. Middle East and Africa Influenza A Virus, H3N2 Subtype Infections Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 67. Influenza A Virus, H3N2 Subtype Infections Drug Value Chain Figure 68. Key Raw Materials Price Figure 69. Manufacturing Cost Structure Figure 70. Influenza A Virus, H3N2 Subtype Infections Drug Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • NVINF-1
  • NSC-61610
  • NP-025
  • NEO-8877
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Johnson & Johnson
  • AbbVie Inc
  • Zydus Cadila Healthcare Limited
  • Visterra, Inc.
  • VBI Vaccines Inc.
  • Sarepta Therapeutics, Inc.
  • OPKO Health, Inc.
  • NanoViricides, Inc.
  • Mucosis B.V.
  • MedImmune, LLC
  • Medicago Inc.
  • Inovio Pharmaceuticals, Inc.
  • ILiAD Biotechnologies, LLC
  • Glide Pharmaceutical Technologies Limited
  • FluGen, Inc.
  • Celltrion, Inc.
  • Aphios Corporation
  • AIMM Therapeutics B.V.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Influenza A Virus, H3N2 Subtype Infections Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Influenza A Virus, H3N2 Subtype Infections Drug Market by Type
  6. 1.3.1 NVINF-1
  7. 1.3.2 NSC-61610
  8. 1.3.3 NP-025
  9. 1.3.4 NEO-8877
  10. 1.3.5 Others
  11. 1.4 Global Influenza A Virus, H3N2 Subtype Infections Drug Market Size by Type
  12. 1.4.1 Global Influenza A Virus, H3N2 Subtype Infections Drug Market Size Overview by Type (2021-2032)
  13. 1.4.2 Global Influenza A Virus, H3N2 Subtype Infections Drug Historic Market Size Review by Type (2021-2026)
  14. 1.4.3 Global Influenza A Virus, H3N2 Subtype Infections Drug Forecasted Market Size by Type (2027-2032)
  15. 1.5 Key Regions Market Size by Type
  16. 1.5.1 North America Influenza A Virus, H3N2 Subtype Infections Drug Sales Breakdown by Type (2021-2026)
  17. 1.5.2 Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales Breakdown by Type (2021-2026)
  18. 1.5.3 Asia-Pacific Influenza A Virus, H3N2 Subtype Infections Drug Sales Breakdown by Type (2021-2026)
  19. 1.5.4 South America Influenza A Virus, H3N2 Subtype Infections Drug Sales Breakdown by Type (2021-2026)
  20. 1.5.5 Middle East and Africa Influenza A Virus, H3N2 Subtype Infections Drug Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Influenza A Virus, H3N2 Subtype Infections Drug Industry Trends
  2. 2.2 Influenza A Virus, H3N2 Subtype Infections Drug Industry Drivers
  3. 2.3 Influenza A Virus, H3N2 Subtype Infections Drug Industry Opportunities and Challenges
  4. 2.4 Influenza A Virus, H3N2 Subtype Infections Drug Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Influenza A Virus, H3N2 Subtype Infections Drug Revenue (2021-2026)
  2. 3.2 Global Top Players by Influenza A Virus, H3N2 Subtype Infections Drug Sales (2021-2026)
  3. 3.3 Global Top Players by Influenza A Virus, H3N2 Subtype Infections Drug Price (2021-2026)
  4. 3.4 Global Influenza A Virus, H3N2 Subtype Infections Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Influenza A Virus, H3N2 Subtype Infections Drug Major Company Production Sites & Headquarters
  6. 3.6 Global Influenza A Virus, H3N2 Subtype Infections Drug Company, Product Type & Application
  7. 3.7 Global Influenza A Virus, H3N2 Subtype Infections Drug Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Influenza A Virus, H3N2 Subtype Infections Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Influenza A Virus, H3N2 Subtype Infections Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Influenza A Virus, H3N2 Subtype Infections Drug Tier 1, Tier 2, and Tier 3
4 Influenza A Virus, H3N2 Subtype Infections Drug Regional Status and Outlook
  1. 4.1 Global Influenza A Virus, H3N2 Subtype Infections Drug Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Influenza A Virus, H3N2 Subtype Infections Drug Historic Market Size by Region
  3. 4.2.1 Global Influenza A Virus, H3N2 Subtype Infections Drug Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Influenza A Virus, H3N2 Subtype Infections Drug Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Influenza A Virus, H3N2 Subtype Infections Drug Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Influenza A Virus, H3N2 Subtype Infections Drug Forecasted Market Size by Region
  7. 4.3.1 Global Influenza A Virus, H3N2 Subtype Infections Drug Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Influenza A Virus, H3N2 Subtype Infections Drug Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Influenza A Virus, H3N2 Subtype Infections Drug Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Influenza A Virus, H3N2 Subtype Infections Drug by Application
  1. 5.1 Influenza A Virus, H3N2 Subtype Infections Drug Market by Application
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Others
  5. 5.2 Global Influenza A Virus, H3N2 Subtype Infections Drug Market Size by Application
  6. 5.2.1 Global Influenza A Virus, H3N2 Subtype Infections Drug Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Influenza A Virus, H3N2 Subtype Infections Drug Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Influenza A Virus, H3N2 Subtype Infections Drug Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Influenza A Virus, H3N2 Subtype Infections Drug Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Influenza A Virus, H3N2 Subtype Infections Drug Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Influenza A Virus, H3N2 Subtype Infections Drug Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Influenza A Virus, H3N2 Subtype Infections Drug Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Johnson & Johnson
  2. 6.1.1 Johnson & Johnson Company Information
  3. 6.1.2 Johnson & Johnson Business Overview
  4. 6.1.3 Johnson & Johnson Influenza A Virus, H3N2 Subtype Infections Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Johnson & Johnson Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio
  6. 6.1.5 Johnson & Johnson Recent Developments
  7. 6.2 AbbVie Inc
  8. 6.2.1 AbbVie Inc Company Information
  9. 6.2.2 AbbVie Inc Business Overview
  10. 6.2.3 AbbVie Inc Influenza A Virus, H3N2 Subtype Infections Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 AbbVie Inc Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio
  12. 6.2.5 AbbVie Inc Recent Developments
  13. 6.3 Zydus Cadila Healthcare Limited
  14. 6.3.1 Zydus Cadila Healthcare Limited Company Information
  15. 6.3.2 Zydus Cadila Healthcare Limited Business Overview
  16. 6.3.3 Zydus Cadila Healthcare Limited Influenza A Virus, H3N2 Subtype Infections Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Zydus Cadila Healthcare Limited Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio
  18. 6.3.5 Zydus Cadila Healthcare Limited Recent Developments
  19. 6.4 Visterra, Inc.
  20. 6.4.1 Visterra, Inc. Company Information
  21. 6.4.2 Visterra, Inc. Business Overview
  22. 6.4.3 Visterra, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Visterra, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio
  24. 6.4.5 Visterra, Inc. Recent Developments
  25. 6.5 VBI Vaccines Inc.
  26. 6.5.1 VBI Vaccines Inc. Company Information
  27. 6.5.2 VBI Vaccines Inc. Business Overview
  28. 6.5.3 VBI Vaccines Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 VBI Vaccines Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio
  30. 6.5.5 VBI Vaccines Inc. Recent Developments
  31. 6.6 Sarepta Therapeutics, Inc.
  32. 6.6.1 Sarepta Therapeutics, Inc. Company Information
  33. 6.6.2 Sarepta Therapeutics, Inc. Business Overview
  34. 6.6.3 Sarepta Therapeutics, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Sarepta Therapeutics, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio
  36. 6.6.5 Sarepta Therapeutics, Inc. Recent Developments
  37. 6.7 OPKO Health, Inc.
  38. 6.7.1 OPKO Health, Inc. Company Information
  39. 6.7.2 OPKO Health, Inc. Business Overview
  40. 6.7.3 OPKO Health, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 OPKO Health, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio
  42. 6.7.5 OPKO Health, Inc. Recent Developments
  43. 6.8 NanoViricides, Inc.
  44. 6.8.1 NanoViricides, Inc. Company Information
  45. 6.8.2 NanoViricides, Inc. Business Overview
  46. 6.8.3 NanoViricides, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 NanoViricides, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio
  48. 6.8.5 NanoViricides, Inc. Recent Developments
  49. 6.9 Mucosis B.V.
  50. 6.9.1 Mucosis B.V. Company Information
  51. 6.9.2 Mucosis B.V. Business Overview
  52. 6.9.3 Mucosis B.V. Influenza A Virus, H3N2 Subtype Infections Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Mucosis B.V. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio
  54. 6.9.5 Mucosis B.V. Recent Developments
  55. 6.10 MedImmune, LLC
  56. 6.10.1 MedImmune, LLC Company Information
  57. 6.10.2 MedImmune, LLC Business Overview
  58. 6.10.3 MedImmune, LLC Influenza A Virus, H3N2 Subtype Infections Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 MedImmune, LLC Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio
  60. 6.10.5 MedImmune, LLC Recent Developments
  61. 6.11 Medicago Inc.
  62. 6.11.1 Medicago Inc. Company Information
  63. 6.11.2 Medicago Inc. Business Overview
  64. 6.11.3 Medicago Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Medicago Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio
  66. 6.11.5 Medicago Inc. Recent Developments
  67. 6.12 Inovio Pharmaceuticals, Inc.
  68. 6.12.1 Inovio Pharmaceuticals, Inc. Company Information
  69. 6.12.2 Inovio Pharmaceuticals, Inc. Business Overview
  70. 6.12.3 Inovio Pharmaceuticals, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Inovio Pharmaceuticals, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio
  72. 6.12.5 Inovio Pharmaceuticals, Inc. Recent Developments
  73. 6.13 ILiAD Biotechnologies, LLC
  74. 6.13.1 ILiAD Biotechnologies, LLC Company Information
  75. 6.13.2 ILiAD Biotechnologies, LLC Business Overview
  76. 6.13.3 ILiAD Biotechnologies, LLC Influenza A Virus, H3N2 Subtype Infections Drug Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 ILiAD Biotechnologies, LLC Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio
  78. 6.13.5 ILiAD Biotechnologies, LLC Recent Developments
  79. 6.14 Glide Pharmaceutical Technologies Limited
  80. 6.14.1 Glide Pharmaceutical Technologies Limited Company Information
  81. 6.14.2 Glide Pharmaceutical Technologies Limited Business Overview
  82. 6.14.3 Glide Pharmaceutical Technologies Limited Influenza A Virus, H3N2 Subtype Infections Drug Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Glide Pharmaceutical Technologies Limited Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio
  84. 6.14.5 Glide Pharmaceutical Technologies Limited Recent Developments
  85. 6.15 FluGen, Inc.
  86. 6.15.1 FluGen, Inc. Company Information
  87. 6.15.2 FluGen, Inc. Business Overview
  88. 6.15.3 FluGen, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 FluGen, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio
  90. 6.15.5 FluGen, Inc. Recent Developments
  91. 6.16 Celltrion, Inc.
  92. 6.16.1 Celltrion, Inc. Company Information
  93. 6.16.2 Celltrion, Inc. Business Overview
  94. 6.16.3 Celltrion, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Celltrion, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio
  96. 6.16.5 Celltrion, Inc. Recent Developments
  97. 6.17 Aphios Corporation
  98. 6.17.1 Aphios Corporation Company Information
  99. 6.17.2 Aphios Corporation Business Overview
  100. 6.17.3 Aphios Corporation Influenza A Virus, H3N2 Subtype Infections Drug Sales, Revenue and Gross Margin (2021-2026)
  101. 6.17.4 Aphios Corporation Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio
  102. 6.17.5 Aphios Corporation Recent Developments
  103. 6.18 AIMM Therapeutics B.V.
  104. 6.18.1 AIMM Therapeutics B.V. Company Information
  105. 6.18.2 AIMM Therapeutics B.V. Business Overview
  106. 6.18.3 AIMM Therapeutics B.V. Influenza A Virus, H3N2 Subtype Infections Drug Sales, Revenue and Gross Margin (2021-2026)
  107. 6.18.4 AIMM Therapeutics B.V. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio
  108. 6.18.5 AIMM Therapeutics B.V. Recent Developments
7 North America by Country
  1. 7.1 North America Influenza A Virus, H3N2 Subtype Infections Drug Sales by Country
  2. 7.1.1 North America Influenza A Virus, H3N2 Subtype Infections Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Influenza A Virus, H3N2 Subtype Infections Drug Sales by Country (2021-2026)
  4. 7.1.3 North America Influenza A Virus, H3N2 Subtype Infections Drug Sales Forecast by Country (2027-2032)
  5. 7.2 North America Influenza A Virus, H3N2 Subtype Infections Drug Market Size by Country
  6. 7.2.1 North America Influenza A Virus, H3N2 Subtype Infections Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Influenza A Virus, H3N2 Subtype Infections Drug Market Size by Country (2021-2026)
  8. 7.2.3 North America Influenza A Virus, H3N2 Subtype Infections Drug Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales by Country
  2. 8.1.1 Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales by Country (2021-2026)
  4. 8.1.3 Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Influenza A Virus, H3N2 Subtype Infections Drug Market Size by Country
  6. 8.2.1 Europe Influenza A Virus, H3N2 Subtype Infections Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Influenza A Virus, H3N2 Subtype Infections Drug Market Size by Country (2021-2026)
  8. 8.2.3 Europe Influenza A Virus, H3N2 Subtype Infections Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Influenza A Virus, H3N2 Subtype Infections Drug Sales by Country
  2. 9.1.1 Asia-Pacific Influenza A Virus, H3N2 Subtype Infections Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Influenza A Virus, H3N2 Subtype Infections Drug Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Influenza A Virus, H3N2 Subtype Infections Drug Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Influenza A Virus, H3N2 Subtype Infections Drug Market Size by Country
  6. 9.2.1 Asia-Pacific Influenza A Virus, H3N2 Subtype Infections Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Influenza A Virus, H3N2 Subtype Infections Drug Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Influenza A Virus, H3N2 Subtype Infections Drug Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Influenza A Virus, H3N2 Subtype Infections Drug Sales by Country
  2. 10.1.1 South America Influenza A Virus, H3N2 Subtype Infections Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Influenza A Virus, H3N2 Subtype Infections Drug Sales by Country (2021-2026)
  4. 10.1.3 South America Influenza A Virus, H3N2 Subtype Infections Drug Sales Forecast by Country (2027-2032)
  5. 10.2 South America Influenza A Virus, H3N2 Subtype Infections Drug Market Size by Country
  6. 10.2.1 South America Influenza A Virus, H3N2 Subtype Infections Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Influenza A Virus, H3N2 Subtype Infections Drug Market Size by Country (2021-2026)
  8. 10.2.3 South America Influenza A Virus, H3N2 Subtype Infections Drug Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Influenza A Virus, H3N2 Subtype Infections Drug Sales by Country
  2. 11.1.1 Middle East and Africa Influenza A Virus, H3N2 Subtype Infections Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Influenza A Virus, H3N2 Subtype Infections Drug Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Influenza A Virus, H3N2 Subtype Infections Drug Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Influenza A Virus, H3N2 Subtype Infections Drug Market Size by Country
  6. 11.2.1 Middle East and Africa Influenza A Virus, H3N2 Subtype Infections Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Influenza A Virus, H3N2 Subtype Infections Drug Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Influenza A Virus, H3N2 Subtype Infections Drug Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Influenza A Virus, H3N2 Subtype Infections Drug Value Chain Analysis
  2. 12.1.1 Influenza A Virus, H3N2 Subtype Infections Drug Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Influenza A Virus, H3N2 Subtype Infections Drug Production Mode & Process
  7. 12.2 Influenza A Virus, H3N2 Subtype Infections Drug Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Influenza A Virus, H3N2 Subtype Infections Drug Distributors
  10. 12.2.3 Influenza A Virus, H3N2 Subtype Infections Drug Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst